You can buy or sell CYTX and other stocks, options, ETFs, and crypto commission-free!
Cytori Therapeutics Inc. Common Stock, also called Cytori Therapeutics, is a late stage cell therapy company which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Read More It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Associated PressMar 7
Cytori Files Pre-submission Request for New Drug Application
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that it officially filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Dox...
Stock Price, News, & Analysis for Cytori Therapeutics
Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has complet...
-$0.30 per share
Expected Mar 27, After Hours